Pfizer, Inc. (PFE) research, news, and more from GeoInvesting

Company description

Fri, 02 Feb 2018 14:14:40 GMT

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines, as well as products for consumer healthcare. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.

Comments & Business Outlook

Fri, 28 Aug 2009 04:00:00 GMT

“Our results this quarter demonstrate our ability to continue to deliver solid operational performance despite a challenging and dynamic economic and operating environment. On a constant currency basis, all of our Pharmaceutical units and Animal Health generated revenue growth during the quarter, with the exception of the Established Products unit, which manages a portfolio of products that have an expected decline in revenues at this stage of their lifecycle,” stated Jeff Kindler, Chairman and Chief Executive Officer.

Frank D’Amelio, Chief Financial Officer, stated, “We remain committed to delivering on our 2009 financial goals and today, are increasing our guidance.

FULL YEAR 2009 Guidance Ending December^a

	Full Year 2009 Guidance	Full Year 2008 Reported	Period Change
GAAP Revenue	$45.0 to $46.0 billion	$48.3 billion	-6.8% to -47.6%
GAAP EPS ^b	$1.30 to $1.45	$1.20	8.3% to 20.8%
Non-GAAP EPS ^b	$1.90 to $2.00	$2.42	-21.5% to -17.4%

Source: See Release, July 22, 2009

^a The above forecasts reflect the Company's current and preliminary views and are therefore subject to change. Please refer to the Company's Safe Harbor Statement (usually in press releases) for the factors that could cause actual results to differ materially from those contained in any forward-looking statement.

^b Non-GAAP EPS figures generally exclude certain non-operating gains and losses as well as certain non-cash items. Non-GAAP information should not be viewed in isolation or as a substitute for reported, or GAAP information . For a more complete explanation of the company's definition of non-GAAP please refer to its financial press releases. The GeoTeam® non-GAAP figures may, from time to time, differ from company supplied figures.

Comments & Business Outlook

Sun, 19 Jul 2009 04:00:00 GMT

Per an April 28, 2009 press release, Pfizer’s financial full-year 2009, guidance is unchanged from the guidance provided on January 26, 2009, except for reported diluted EPS, which has been reduced to a range of $1.20 to $1.35 from $1.34 to $1.49 to reflect certain costs incurred and expected to be incurred in connection with the pending Wyeth acquisition.

Comments & Business Outlook

Mon, 26 Jan 2009 05:00:00 GMT

Guidance Report:

	2008 Actual	2009 Guidance
Adjusted Revenues	$48.3 billion	$44.0 to $46.0 billion
Effective Tax Rate on Adjusted Income	22.0%	Approx. 30%
Reported Diluted EPS	$1.20	$1.34 to $1.49
Adjusted Diluted EPS	$2.42	$1.85 to $1.95

Source: Business Wire (January 26, 2009)